|
KMID : 1141720160040010010
|
|
폐쇄성폐질환
2016 Volume.4 No. 1 p.10 ~ p.10
|
|
|
|
|
Oh Yeon-Mok
|
|
|
Abstract
|
|
|
|
An inhaled long-acting bronchodilator hascontributed to the treatment of COPD patients as powerfully as to have changed the disease concept of COPD from an irreversible disease to a treatable disease. Recently a new generation of inhaled long-acting bronchodilators are becoming available. Among them, a dual bronchodilator or a fixed combination of long-acting muscarinic antagonist and long-acting beta-agonist has shown at least 150% as effective as a single componentin terms of symptom improvement, health-related quality of life, lung function improvement, and exacerbation prevention. The dual bronchodilator is expected to contribute one step further to the treatment of COPD.
|
|
|
KEYWORD
|
|
|
COPD, bronchodilator, long-acting muscarinic antagonist, long-acting beta-agonist
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|